Finch Therapeutics(FNCH)

Focus: Finch Therapeutics is a Boston-based public biotech focused on microbiological therapy, developing live biotherapeutic products (LBPs) derived from fecal microbiota for infectious and neurological indications. The company is in early commercialization stage with minimal revenue generation.

Unknown

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$90M

Open Jobs

About Finch Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Finch Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$861K

Pipeline & Clinical Trials

Physical examination

Anal Intraepithelial Neoplasia

N/A

Clinical Trials (1)

NCT05858021COrSIcA: Disease Measurement

N/A

Help build intelligence for Finch Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneer in live biotherapeutic modality with multiple programs across infectious disease and neurology addressing underserved indications like C. difficile and autism spectrum disorder.
Public company status provides liquidity and institutional infrastructure despite pre-commercial revenue profile.
Early-stage pipeline offers hands-on impact in drug development with clear Phase 2/3 progression catalysts expected.

Watch Out For

Extreme R&D intensity (6140%) relative to revenue signals unsustainable cash burn; FY 2023 revenue of $861K against $53M R&D spend, with net losses of $114.6M.
Cash position declined 46% year-over-year ($133M to $71M) at current burn rate, creating material liquidity risk within 12-18 months without additional funding or revenue inflection.
Minimal hiring activity (1 active role in IT) suggests organizational contraction or preservation mode despite pipeline advancement.
Microbiological therapy remains scientifically and commercially unproven; regulatory pathway and manufacturing scalability remain uncertain.

Generated by Claude from Finch Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Fecal Microbiota Transplantation

Enterobacteriaceae Infections

Phase 1

CP101

Clostridium Difficile Infection

Phase 2

Clinical Trials (1)

NCT03497806Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Phase 2

Full Spectrum Microbiota

Clostridium Difficile Infection Recurrence

Phase 2

Clinical Trials (1)

NCT03110133Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

Phase 2

CP101

Autism Spectrum Disorder

Phase 2

Clinical Trials (1)

NCT03829878Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)

Phase 2

CP101

Recurrent C. Difficile Infection

Phase 3

Clinical Trials (1)

NCT05153499A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2023)

Revenue

$861K95%

R&D Spend

$53M(6140%)8%

Net Income

-$115M

Cash

$71M

Source: SEC 10-K Filing